Interagency Task Force Identifies Point-of-Care Diagnostics As Top Priority
This article was originally published in The Gray Sheet
The ongoing research and development of new accurate, affordable, rapid diagnostic methods to facilitate appropriate use of antimicrobials should be a major government-wide priority, according to the Jan. 18 action plan issued by the Interagency Task Force on Antimicrobial Resistance.
You may also be interested in...
FDA will likely not require additional post-market surveillance from companies manufacturing automated short-term incubation cycle (STIC) antimicrobial susceptibility devices (ASDs), the agency says in the March 8 Federal Register.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.